



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6: C12N 15/19, C07K 14/52, C12P 21/02, C07K 14/715, 16/28, A61K 38/19, 38/17, G01N 33/68, A61K 39/395</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/07985 (43) International Publication Date: 23 March 1995 (23.03.95)</p>
<p>(21) International Application Number: PCT/GB94/02006 (22) International Filing Date: 14 September 1994 (14.09.94)</p>	<p>(74) Agents: SILVESTON, Judith et al.; Abel & Inury, Northumbria House, 303-306 High Holborn, London WC1V 7LH (GB).</p>	
<p>(30) Priority Data: 9318984.3 14 September 1993 (14.09.93) GB 9408602.2 29 April 1994 (29.04.94) GB</p>	<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).</p>	
<p>(71) Applicants (for all designated States except US): NATIONAL HEART & LUNG INSTITUTE (GB/GB); Dovehouse Street, London SW3 6LY (GB); LUDWIG INSTITUTE FOR CANCER RESEARCH (GB/GB); Hedges House, 153-155 Regent Street, London W1R 7FD (GB).</p>	<p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(72) Inventors; and (75) Inventors/Applicants (for US only): WILLIAMS, Timothy, John (GB/GB); National Heart & Lung Institute, Dovehouse Street, London SW3 6LY (GB); JOSE, Peter, John (GB/GB); National Heart & Lung Institute, Dovehouse Street, London SW3 6LY (GB); GRIFFITHS-JOHNSON, David, A. (GB/GB); National Heart & Lung Institute, Dovehouse Street, London SW3 6LY (GB); HSUAN, John, Justin (GB/GB); Ludwig Institute for Cancer Research, Hedges House, 153-155 Regent Street, London W1R 7FD (GB).</p>		
<p>(54) Title: EOTAXIN: EOSINOPHIL CHEMOTACTIC CYTOKINE</p>		
<p>(57) Abstract</p> <p>A chemoattractant protein called "eotaxin" is capable of attracting eosinophils and of inducing eosinophil accumulation and/or activation in vitro and in vivo. Various types of agents that inhibit or otherwise hinder the production, release or activity of eotaxin may be used therapeutically in the treatment of asthma and other inflammatory diseases.</p> <div data-bbox="433 718 814 777"> <p>15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100</p> <p>MSPTFACCTVYVANKISTFQRLKSTKSTTSKCPQATVTEIKFQDKHCAQFKNQVQANTLQIQQKTTQ</p> <p>Non-terminal residues</p> <p>71 72 73 74 75</p> </div> <div data-bbox="415 942 798 1205"> <p>gunes-pig skin</p> <p>240 min</p> <p>30 min</p> <p>125I-Eosinophils per site</p> <p>4000</p> <p>2000</p> <p>0</p> <p>0.1 1 10 100 1 10 100 1 10 100</p> <p>EOTAXIN RANTES MCP-1</p> <p>(pmol per site)</p> <p>Inset: gunes-pig eosinophils</p> <p>1.0</p> <p>0.5</p> <p>0</p> <p>10⁻¹⁰ 10⁻⁹ 10⁻⁸ 10⁻⁷</p> <p>Concentration (M)</p> <p>EOTAXIN</p> <p>RANTES</p> </div>		